NCT04563936View on ClinicalTrials.gov

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

March 9, 2021

Study Completion Date

March 9, 2021

Conditions
Prostate Cancer
Interventions
DRUG

LY01005 3.6 mg

LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.

DRUG

ZOLADEX® 3.6 mg

ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04563936 - Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | Biotech Hunter | Biotech Hunter